TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
Ticker SymbolTELA
Company nameTELA Bio Inc
IPO dateNov 08, 2019
CEOMr. Antony Koblish
Number of employees209
Security typeOrdinary Share
Fiscal year-endNov 08
Address1 Great Valley Parkway, Suite 24
CityMALVERN
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code19355
Phone14843202930
Websitehttps://www.telabio.com/
Ticker SymbolTELA
IPO dateNov 08, 2019
CEOMr. Antony Koblish
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data